TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.91 Million USD | -59.0% |
| 2022 | 26.62 Million USD | 79.34% |
| 2021 | 14.84 Million USD | 20.03% |
| 2020 | 12.36 Million USD | -19.82% |
| 2019 | 15.42 Million USD | -19.7% |
| 2018 | 19.2 Million USD | 0.33% |
| 2017 | 19.14 Million USD | 10.06% |
| 2016 | 17.39 Million USD | -22.84% |
| 2015 | 22.54 Million USD | -67.95% |
| 2014 | 70.34 Million USD | 153.38% |
| 2013 | 27.76 Million USD | 36.94% |
| 2012 | 20.27 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 11.11 Million USD | 1.86% |
| 2024 Q2 | 10.48 Million USD | -5.65% |
| 2023 FY | 10.91 Million USD | -59.0% |
| 2023 Q2 | 27.92 Million USD | 44.0% |
| 2023 Q4 | 10.91 Million USD | -12.67% |
| 2023 Q3 | 12.49 Million USD | -55.25% |
| 2023 Q1 | 19.39 Million USD | -27.14% |
| 2022 FY | 26.62 Million USD | 79.34% |
| 2022 Q2 | 13.13 Million USD | -18.28% |
| 2022 Q1 | 16.07 Million USD | 8.29% |
| 2022 Q4 | 26.62 Million USD | 19.37% |
| 2022 Q3 | 22.3 Million USD | 69.78% |
| 2021 Q2 | 14.88 Million USD | 31.79% |
| 2021 Q1 | 11.29 Million USD | -8.64% |
| 2021 FY | 14.84 Million USD | 20.03% |
| 2021 Q4 | 14.84 Million USD | 6.44% |
| 2021 Q3 | 13.94 Million USD | -6.33% |
| 2020 Q2 | 12.64 Million USD | -2.45% |
| 2020 Q1 | 12.96 Million USD | -15.94% |
| 2020 Q4 | 12.36 Million USD | -1.66% |
| 2020 FY | 12.36 Million USD | -19.82% |
| 2020 Q3 | 12.57 Million USD | -0.57% |
| 2019 FY | 15.42 Million USD | -19.7% |
| 2019 Q2 | 19.03 Million USD | -1.81% |
| 2019 Q3 | 17.17 Million USD | -9.75% |
| 2019 Q4 | 15.42 Million USD | -10.21% |
| 2019 Q1 | 19.38 Million USD | 0.92% |
| 2018 FY | 19.2 Million USD | 0.33% |
| 2018 Q4 | 19.2 Million USD | -3.64% |
| 2018 Q3 | 19.93 Million USD | 10.97% |
| 2018 Q2 | 17.96 Million USD | -15.96% |
| 2018 Q1 | 21.37 Million USD | 11.64% |
| 2017 Q2 | 15.59 Million USD | 4.44% |
| 2017 FY | 19.14 Million USD | 10.06% |
| 2017 Q1 | 14.93 Million USD | -14.15% |
| 2017 Q4 | 19.14 Million USD | 23.03% |
| 2017 Q3 | 15.56 Million USD | -0.22% |
| 2016 Q1 | 21.67 Million USD | -3.88% |
| 2016 FY | 17.39 Million USD | -22.84% |
| 2016 Q4 | 17.39 Million USD | -7.63% |
| 2016 Q3 | 18.83 Million USD | -4.93% |
| 2016 Q2 | 19.8 Million USD | -8.6% |
| 2015 Q2 | 18.87 Million USD | 5.22% |
| 2015 FY | 22.54 Million USD | -67.95% |
| 2015 Q3 | 18.98 Million USD | 0.58% |
| 2015 Q4 | 22.54 Million USD | 18.78% |
| 2015 Q1 | 17.93 Million USD | -74.5% |
| 2014 FY | 70.34 Million USD | 153.38% |
| 2014 Q3 | 20.91 Million USD | 18.85% |
| 2014 Q4 | 70.34 Million USD | 236.27% |
| 2014 Q2 | 17.6 Million USD | 33.35% |
| 2014 Q1 | 13.19 Million USD | -52.46% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 27.76 Million USD | 36.94% |
| 2013 Q4 | 27.76 Million USD | 0.0% |
| 2012 FY | 20.27 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -126.199% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -359.343% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 71.963% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 91.771% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -292.731% |
| Better Therapeutics, Inc. | 23.84 Million USD | 54.224% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -31.748% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -9.422% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 58.563% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 65.661% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 84.281% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -37.359% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 77.315% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 93.063% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -211.299% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 48.736% |
| Molecular Templates, Inc. | 31.17 Million USD | 64.987% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 12.792% |
| NexImmune, Inc. | 5.08 Million USD | -114.664% |
| Orgenesis Inc. | 35.53 Million USD | 69.287% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 33.903% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -3996.632% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -375.487% |
| Scopus BioPharma Inc. | 7.45 Million USD | -46.41% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 97.793% |
| Statera Biopharma, Inc. | 22.67 Million USD | 51.871% |
| Trevena, Inc. | 48.26 Million USD | 77.386% |
| Vaxxinity, Inc. | 30.94 Million USD | 64.73% |
| Vaccinex, Inc. | 5.94 Million USD | -83.676% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -454.478% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 71.558% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -295.212% |